College Stock: Penny Stock News

This afternoon, $IVOB announced the results of a clinical trial from their first INVO center in South America. The results show a 36% ongoing pregnancy rate per cycle.

The Center for Disease Control and Prevention (CDC) reports a 35% success rate for conventional IVF treatments in the United States. But what does that mean? In 2006, a report on assisted reproductive technology (ART) showed 80,313 embryos were transferred during IVF procedures and resulted in 28,404 live-birth deliveries—that makes for a “success rate” of 35%.

In 2007, a report from the same source followed 430 fertility clinics in the United States and showed that 142,415 ART cycles resulted in 43,408 live-birth pregnancies—a lower, 30.5 % success rate.

$IVOB‘s news today is extremely significant because it provides clinical evidence that the INVO procedure is officially comparable to conventional IVF treatments currently being used.

The Dean has been teaching the CollegeStock Community about $IVOB for months and now they should know that $IVOB‘s INVO procedure could quite possibly become the most favorable infertility treatment on the market.

For months, The Dean has taught the CollegeStock Community that $IVOB‘s INVO procedure is less expensive, more natural and aims to result in fewer multiple-birth pregnancies—making it safer for mothers and babies. And because the American Society of Reproductive Medicine (ASRM) suggests a maximum of 2 embryos to be transferred per patient, $IVOB‘s INVO procedure is already following guidelines for the United States.

In addition, today’s press release from $IVOB suggests that Dr. Elkin Lucina, owner and operating physician of the CECOFLES fertility center in Columbia “expect[s] to perform INVO in replacement of conventional IVF.” And, since CECOFLES operates “several INVO clinics within the region,” The Dean believes Dr. Lucina will ensure that INVO becomes the standard fertility treatment at these clinics.

$IVOB‘s INVO procedure allows for conception and embryo development to take place more naturally, inside the female patient. This means that doctors, such as Lucina, do not have to spend a lot of money on electricity and other equipment necessary to simulate the physical conditions (temperature, oxygen and nitrogen levels, pH) inside a woman’s body.

The Dean believes $IVOB‘s INVOcell device is cost effective because the expenses of IVF clinics and labs become virtually non-existent so they don’t have to be passed down to the millions of infertile couples looking for a more cost-effective infertility treatment.

The Dean thinks $IVOB‘s INVO procedure is a win-win for infertile couples and The Dean’s Billion Dollar Baby could soon be born.